Cotellic and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Cotellic (cobimetinib fumarate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zelboraf, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Weakness when taking Cotellic. It is created by eHealthMe based on reports of 1,908 people who have side effects when taking Cotellic from the FDA, and is updated regularly.

What is Cotellic?

Cotellic has active ingredients of cobimetinib fumarate. eHealthMe is studying from 1,908 Cotellic users. Check the latest studies of Cotellic.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,612 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 21, 2026

1,908 people reported to have side effects when taking Cotellic.
Among them, 82 people (4.3%) have Weakness.

Among these 82 people:

How long have people been on Cotellic when they have Weakness? *

What is the gender of people who have Weakness when taking Cotellic? *

female: 51.95 %
male: 48.05 %

What is the age of people who have Weakness when taking Cotellic? *

What are other drugs people take besides Cotellic? *

What are other side effects people have besides Weakness? *

Diarrhea: 31 people, 37.80%
Fever: 25 people, 30.49%
Rashes (redness): 22 people, 26.83%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 21 people, 25.61%
Nausea (feeling of having an urge to vomit): 19 people, 23.17%
Fatigue (feeling of tiredness): 18 people, 21.95%
Nausea And Vomiting: 15 people, 18.29%
Dizziness: 12 people, 14.63%
Weight Decreased: 9 people, 10.98%
Anaemia (lack of blood): 9 people, 10.98%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 36 people, 43.90%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 29 people, 35.37%
Type 2 Diabetes: 3 people, 3.66%
Enlarged Prostate: 3 people, 3.66%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 3.66%
Dyslipidaemia (abnormal amount of lipids): 3 people, 3.66%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 3 people, 3.66%
Metastases To Central Nervous System (cancer spreads to central nervous system): 3 people, 3.66%
Hyperglycemia (high blood sugar): 3 people, 3.66%
Colon Cancer: 2 people, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Cotellic and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cotellic:

Cotellic (1,908 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Cotellic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,612 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cobimetinib fumarate (the active ingredients of Cotellic) and Cotellic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.